Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2003
10/08/2003CN1123566C Arylsulfonyl hydroxamic acid derivatives
10/08/2003CN1123358C Oral liquid for treating cerebrovascular disease
10/08/2003CN1123357C Medicine for wholly conditioning viscera
10/08/2003CN1123352C Cold eliminating pills
10/08/2003CN1123342C Use of inhibitors of renin-angiotension system
10/07/2003US6630579 Complex
10/07/2003US6630573 Tau-conotoxin peptides
10/07/2003US6630516 Application of an effective, non-toxic amount of at least one active ingredient that inhibits MMPs and promotes procollagen synthesis; especially a retinoid selected from retinol, retinal, retinoic acid, or a retinoic acid salt
10/07/2003US6630512 Cell adhesion inhibitors
10/07/2003US6630510 Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
10/07/2003US6630507 Cannabinoids as antioxidants and neuroprotectants
10/07/2003US6630505 Aminopyrrolidine sulfonamides as serine protease inhibitors
10/07/2003US6630504 Phenoxyphenylheterocyclyl derivatives as SSRIs
10/07/2003US6630503 Cell adhesion inhibitors
10/07/2003US6630502 Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
10/07/2003US6630501 Phosphinic pseudo-peptides that may be used as matrix zinc metalloprotease inhibitors
10/07/2003US6630500 Treating angiogenic disorders
10/07/2003US6630493 Heterocyclically substituted amides, their preparation and use
10/07/2003US6630492 Lymphocyte function antigen-1 antagonists
10/07/2003US6630491 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
10/07/2003US6630487 Treatment of insulin resistance with growth hormone secretagogues
10/07/2003US6630485 For therapy of inflammatory disease
10/07/2003US6630483 Phenanthridine-N-oxides
10/07/2003US6630482 CFTR channel activator compounds and pharmaceutical compositions containing same
10/07/2003US6630479 Methods and compositions utilizing quinazolinones
10/07/2003US6630477 Therapeutic nucleoside compound
10/07/2003US6630475 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease
10/07/2003US6630472 Compounds, pharmaceutical compositions, and methods for stimulating neuronal growth and elongation
10/07/2003US6630470 G-CSF mimetics
10/07/2003US6630469 5-HT7 receptor antagonists
10/07/2003US6630468 Disubstituted pyrazolines and triazolines as factor Xa inhibitors
10/07/2003US6630467 Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
10/07/2003US6630466 Anticholinergics which have a long-lasting effect, such as glycopyrronium bromide, tiotropium bromide or an ester of bi-or tricyclic amino alcohol such as a nortropanol
10/07/2003US6630464 Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
10/07/2003US6630463 Heterocycle-containing carboxylic acid derivative and drug containing the same
10/07/2003US6630454 Method and pharmaceutical composition for the treatment of cancer
10/07/2003US6630337 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/07/2003US6630304 Human osteoporosis gene
10/07/2003US6630165 For sustained release; therapy
10/07/2003US6630157 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides
10/07/2003US6630138 Protein C derivatives
10/07/2003CA2302436C Branched alkoxy-substituted 2-aminopyridines
10/07/2003CA2287552C Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
10/07/2003CA2270026C Substituted bicyclic derivatives for treating central nervous system disorders
10/07/2003CA2263957C Diarylmethyl piperazine derivatives as delta opioid agonists
10/07/2003CA2261267C Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease
10/07/2003CA2207286C Localized delivery of factors enhancing survival of transplanted cells
10/07/2003CA2107105C Heterocyclic-cyclic amine derivatives
10/02/2003WO2003080859A1 Tryptophan aminotransferase, indole-3-pyruvate decarboxylase and indole-3-acetaldehyde oxidase as novel targets for herbicides
10/02/2003WO2003080841A1 Calcineurin activators
10/02/2003WO2003080822A1 Placenta-origin mesenchymal cells and medicinal use thereof
10/02/2003WO2003080643A1 Process for producing triterpene derivative
10/02/2003WO2003080641A1 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring substituted with a long chain at the 11beta position
10/02/2003WO2003080633A1 Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative
10/02/2003WO2003080630A2 Phosphate transport inhibitors
10/02/2003WO2003080626A1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
10/02/2003WO2003080625A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
10/02/2003WO2003080620A1 Inhibitors of nucleoside phosphorylases and nucleosidases
10/02/2003WO2003080619A1 Fused bicyclic pyrimidine derivatives
10/02/2003WO2003080612A1 Dipyridodiazepinones as reverse transcriptase inhibitors
10/02/2003WO2003080611A1 Spiro derivatives and adhesion molecule inhibitors comprising the same as the active ingredient
10/02/2003WO2003080610A1 Imidazopyridine derivatives as kinase inhibitors
10/02/2003WO2003080603A1 Benzodiazepine derivative
10/02/2003WO2003080600A1 Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities
10/02/2003WO2003080599A1 Stable hydrate of a muscarinic receptor antagonist
10/02/2003WO2003080594A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
10/02/2003WO2003080592A1 2-pyrone compounds and use thereof
10/02/2003WO2003080586A1 N-sulfonylurea apoptosis promoters
10/02/2003WO2003080585A1 Novel aminobenzamide derivative
10/02/2003WO2003080582A2 Fredericamycin derivatives
10/02/2003WO2003080581A1 Phenanthridinones as parp inhibitors
10/02/2003WO2003080580A2 Quinoline derivatives and their use as 5-ht6 ligands
10/02/2003WO2003080579A1 Novel adamantane derivatives
10/02/2003WO2003080574A1 Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
10/02/2003WO2003080573A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
10/02/2003WO2003080566A2 Hif hydroxylase inhibitors
10/02/2003WO2003080557A1 Substituted 4-aminocyclohexanols
10/02/2003WO2003080556A1 Amine derivative with potassium channel regulatory function, its preparation and use
10/02/2003WO2003080545A2 Substituted phenylacetic acids
10/02/2003WO2003080171A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/02/2003WO2003080125A2 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
10/02/2003WO2003080106A1 Antibody fusion proteins: effective adjuvants of protein vaccination
10/02/2003WO2003080090A1 Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450
10/02/2003WO2003080087A1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation
10/02/2003WO2003080084A1 A process for the extraction of anthocyanins from black rice and composition thereof
10/02/2003WO2003080077A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination
10/02/2003WO2003080071A1 Novel therapeutical use of agonist ligands specific to g2a receptor
10/02/2003WO2003080070A2 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003WO2003080068A1 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
10/02/2003WO2003080064A1 Kinase inhibitors
10/02/2003WO2003080063A1 PREVENTIVES OR REMEDIES FOR DISEAES CAUSED BY eNOS EXPRESSION
10/02/2003WO2003080058A1 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/02/2003WO2003080057A1 Downsized core tablet containing nifedipine
10/02/2003WO2003080054A1 Use of pyridyl amides as inhibitors of angiogenesis
10/02/2003WO2003080049A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003WO2003080047A1 Phosphate prodrugs of fluorooxindoles
10/02/2003WO2003080046A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
10/02/2003WO2003080044A1 Anti-cancer combinations of dmxaa and a nsaid
10/02/2003WO2003080042A1 Decomposition inhibitor for extracellular matrix of cartilage
10/02/2003WO2003080038A1 Preventive or therapeutic agent for kidney disease
1 ... 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 ... 1564